• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫抑制剂联合类固醇与单独使用类固醇治疗过敏性紫癜肾炎的疗效和安全性:一项荟萃分析。

The efficacy and safety of immunosuppressive agents plus steroids compared with steroids alone in the treatment of Henoch-Schönlein purpura nephritis: A meta-analysis.

机构信息

Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.

出版信息

Int Urol Nephrol. 2019 Jun;51(6):975-985. doi: 10.1007/s11255-019-02092-7. Epub 2019 Apr 15.

DOI:10.1007/s11255-019-02092-7
PMID:30989564
Abstract

BACKGROUND

Henoch-Schönlein purpura nephritis (HSPN) is the most severe symptom of Henoch-Schönlein purpura. The role of immunosuppressive agents combined with steroids is controversial in treating HSPN. Our meta-analysis was performed to assess the efficacy and safety of the combined therapy in the treatment of HSPN compared with steroids alone.

METHODS

Cochrane Library, Pubmed, Embase, and Web of Science were searched and Newcastle-Ottawa Scale was used to assess the quality of the literatures. Odds ratios (OR) and standard mean difference (SMD) with a 95% confidence interval (CI) were used for dichotomous and continuous variables. A random-effect model or fixed-effect analysis was applied according to heterogeneity.

RESULTS

A total of 9 articles were selected in our study. HSPN patients treated with combined therapy demonstrated a significant increase in complete remission rates (OR = 1.95; 95% CI 1.17-3.23, P = 0.010) and total remission rates (OR = 2.30 95% CI 1.33-3.98, P = 0.003) when compared with steroids alone. Children seemed to benefit more from combined treatment (OR = 2.45; CI 1.20-5.02, P = 0.014) than adults (OR = 1.56; CI 0.76-3.20, P = 0.225). Additionally, immunosuppressants plus steroids had an advantage on decreasing proteinuria (SMD = 0.28; CI 0.05-0.52, P = 0.019) and increasing the level of serum albumin (SMD = 0.98; CI 0.35-1.60, P = 0.002). However, significant differences were not found in the estimated glomerular filtration rate (eGFR) and rates of side-effects.

CONCLUSION

Administration of immunosuppressive agents combined with steroids may be a superior alternative for HSPN. Nevertheless, long-term, high-quality, large-sample, and multicenter RCTs are required to make the results more convincing.

摘要

背景

过敏性紫癜肾炎(HSPN)是过敏性紫癜最严重的症状。免疫抑制剂联合激素治疗 HSPN 的疗效存在争议。我们的荟萃分析旨在评估与单独使用激素相比,联合治疗在治疗 HSPN 中的疗效和安全性。

方法

我们检索了 Cochrane Library、Pubmed、Embase 和 Web of Science,并使用纽卡斯尔-渥太华量表评估文献质量。二分类变量采用比值比(OR)和标准化均数差(SMD)及其 95%置信区间(CI)表示,连续性变量采用固定或随机效应模型分析。

结果

本研究共纳入 9 项研究。与单独使用激素相比,联合治疗组 HSPN 患者完全缓解率(OR=1.95;95%CI 1.17-3.23,P=0.010)和总缓解率(OR=2.30;95%CI 1.33-3.98,P=0.003)显著升高。儿童似乎比成人更受益于联合治疗(OR=2.45;95%CI 1.20-5.02,P=0.014),而非成人(OR=1.56;95%CI 0.76-3.20,P=0.225)。此外,免疫抑制剂联合激素在降低蛋白尿(SMD=0.28;95%CI 0.05-0.52,P=0.019)和提高血清白蛋白水平(SMD=0.98;95%CI 0.35-1.60,P=0.002)方面具有优势。然而,在估计肾小球滤过率(eGFR)和不良反应发生率方面未发现显著差异。

结论

免疫抑制剂联合激素治疗可能是 HSPN 的一种更好的选择。然而,需要进行长期、高质量、大样本和多中心 RCT 以提高结果的可信度。

相似文献

1
The efficacy and safety of immunosuppressive agents plus steroids compared with steroids alone in the treatment of Henoch-Schönlein purpura nephritis: A meta-analysis.免疫抑制剂联合类固醇与单独使用类固醇治疗过敏性紫癜肾炎的疗效和安全性:一项荟萃分析。
Int Urol Nephrol. 2019 Jun;51(6):975-985. doi: 10.1007/s11255-019-02092-7. Epub 2019 Apr 15.
2
Efficacy of steroid and immunosuppressant combined therapy in Chinese patients with Henoch-Schönlein purpura nephritis: A retrospective study.中文标题:激素和免疫抑制剂联合治疗中国过敏性紫癜肾炎患者的疗效:一项回顾性研究。
Int Immunopharmacol. 2020 Apr;81:106229. doi: 10.1016/j.intimp.2020.106229. Epub 2020 Jan 31.
3
Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents.无新月体的过敏性紫癜性肾炎患儿的临床结局
Pediatr Nephrol. 2017 Jul;32(7):1193-1199. doi: 10.1007/s00467-017-3604-9. Epub 2017 Feb 15.
4
Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.霉酚酸酯与低剂量类固醇联合治疗中度重症过敏性紫癜性肾炎的评估
Med Sci Monit. 2017 May 18;23:2333-2339. doi: 10.12659/msm.904206.
5
Henoch-Schönlein purpura nephritis: initial risk factors and outcomes in a Latin American tertiary center.过敏性紫癜性肾炎:拉丁美洲一家三级中心的初始风险因素和结局。
Clin Rheumatol. 2018 May;37(5):1319-1324. doi: 10.1007/s10067-017-3972-3. Epub 2018 Jan 13.
6
The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.霉酚酸酯联合皮质类固醇诱导过敏性紫癜肾炎缓解。
Am J Nephrol. 2012;36(3):271-7. doi: 10.1159/000341914. Epub 2012 Sep 7.
7
Treatment strategies for Henoch-Schönlein purpura nephritis by histological and clinical severity.根据组织学和临床严重程度制定过敏性紫癜肾炎的治疗策略。
Pediatr Nephrol. 2011 Apr;26(4):563-9. doi: 10.1007/s00467-010-1741-5. Epub 2011 Jan 4.
8
Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.IgA 肾病牛津分类在儿童过敏性紫癜性肾炎中的价值。
J Nephrol. 2018 Apr;31(2):279-286. doi: 10.1007/s40620-017-0457-z. Epub 2017 Nov 28.
9
Clinicopathological features and prognosis of membranoproliferative-like Henoch-Schönlein purpura nephritis in children.儿童膜增生样过敏性紫癜性肾炎的临床病理特征及预后
World J Pediatr. 2015 Nov;11(4):338-45. doi: 10.1007/s12519-014-0527-4. Epub 2014 Nov 20.
10
Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb.儿童过敏性紫癜肾炎 3a 级或 3b 级的临床转归。
Pediatr Nephrol. 2011 Jul;26(7):1083-8. doi: 10.1007/s00467-011-1834-9. Epub 2011 Mar 9.

引用本文的文献

1
Effects of disease severity-based nursing intervention on immune function and IFN-γ, IL-6, and TNF-α for children with IgA vasculitis nephritis.基于疾病严重程度的护理干预对IgA血管炎肾病患儿免疫功能及干扰素-γ、白细胞介素-6和肿瘤坏死因子-α的影响
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun 2. doi: 10.1007/s00210-025-04325-2.
2
Bone Mineral Density and Bone Quality Trends in a Child on Steroid Therapy Who Developed a Vertebral Fracture: A Case Report.一名接受类固醇治疗并发生椎体骨折儿童的骨密度和骨质量变化趋势:病例报告
Cureus. 2025 Apr 21;17(4):e82675. doi: 10.7759/cureus.82675. eCollection 2025 Apr.
3
Proanthocyanidins: A novel approach to Henoch‑Schonlein purpura through balancing immunity and arresting oxidative stress via TLR4/MyD88/NF‑κB signaling pathway (Review).

本文引用的文献

1
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey.成人 IgA 血管炎(过敏性紫癜)的特征和治疗:法国多中心回顾性调查纳入的 260 例患者的数据。
Arthritis Rheumatol. 2017 Sep;69(9):1862-1870. doi: 10.1002/art.40178.
2
Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis.霉酚酸酯与低剂量类固醇联合治疗中度重症过敏性紫癜性肾炎的评估
Med Sci Monit. 2017 May 18;23:2333-2339. doi: 10.12659/msm.904206.
3
Treatment Outcomes in Children with Henoch-Schönlein Nephritis.
原花青素:通过TLR4/MyD88/NF-κB信号通路平衡免疫和抑制氧化应激治疗过敏性紫癜的新方法(综述)
Exp Ther Med. 2023 May 9;25(6):300. doi: 10.3892/etm.2023.11999. eCollection 2023 Jun.
4
Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.基于药物基因组学的个性化用药及儿童IgA血管炎肾炎的治疗进展
Front Pharmacol. 2022 Jul 22;13:956397. doi: 10.3389/fphar.2022.956397. eCollection 2022.
5
Global Glomerulosclerosis and Segmental Glomerulosclerosis Could Serve as Effective Markers for Prognosis and Treatment of IgA Vasculitis With Nephritis.全球肾小球硬化和节段性肾小球硬化可作为IgA血管炎伴肾炎预后和治疗的有效标志物。
Front Med (Lausanne). 2020 Oct 23;7:588031. doi: 10.3389/fmed.2020.588031. eCollection 2020.
6
Pulmonary embolism as the primary presentation of IgA vasculitis.肺栓塞作为 IgA 血管炎的首发表现。
BMJ Case Rep. 2020 Aug 27;13(8):e235884. doi: 10.1136/bcr-2020-235884.
7
Safety and Efficacy Evaluation of Traditional Chinese Medicine (Qingre-Lishi-Yishen Formula) Based on Treatment of Regular Glucocorticoid Combined with Cyclophosphamide Pulse in Children Suffered from Moderately Severe Henoch-Schonlein Purpura Nephritis with Nephrotic Proteinuria.基于常规糖皮质激素联合环磷酰胺冲击治疗儿童中度重度紫癜性肾炎伴肾病性蛋白尿的中药(清热利湿益肾方)安全性与疗效评估
Evid Based Complement Alternat Med. 2020 Jan 27;2020:3920735. doi: 10.1155/2020/3920735. eCollection 2020.
8
Role of p300 in the pathogenesis of Henoch-Schonlein purpura nephritis and as a new target of glucocorticoid therapy in mice.p300 在过敏性紫癜肾炎发病机制中的作用及其作为糖皮质激素治疗靶点在小鼠中的作用。
Chin Med J (Engl). 2019 Aug 20;132(16):1942-1950. doi: 10.1097/CM9.0000000000000380.
过敏性紫癜性肾炎患儿的治疗结果
Adv Exp Med Biol. 2016;912:65-72. doi: 10.1007/5584_2016_231.
4
Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Schönlein purpura nephritis: a retrospective study.霉酚酸酯联合泼尼松诱导紫癜性肾炎缓解:一项回顾性研究
J Zhejiang Univ Sci B. 2015 Sep;16(9):772-9. doi: 10.1631/jzus.B1400335.
5
Comparison between adults and children with Henoch-Schönlein purpura nephritis.成人与儿童过敏性紫癜性肾炎的比较。
Pediatr Nephrol. 2015 May;30(5):791-6. doi: 10.1007/s00467-014-3016-z. Epub 2014 Dec 7.
6
Chapter 11: Henoch-Schönlein purpura nephritis.第11章:过敏性紫癜肾炎。
Kidney Int Suppl (2011). 2012 Jun;2(2):218-220. doi: 10.1038/kisup.2012.24.
7
Leflunomide in addition to steroids improves proteinuria and renal function in adult Henoch-Schoenlein nephritis with nephrotic proteinuria.除类固醇外,来氟米特可改善成人伴肾病性蛋白尿的过敏性紫癜性肾炎的蛋白尿和肾功能。
Nephrology (Carlton). 2014 Feb;19(2):94-100. doi: 10.1111/nep.12175.
8
The relationship between children kidney diseases and adult ESRD--an epidemiological investigation of 700 cases.儿童肾脏病与成人终末期肾病的关系——700 例的流行病学调查。
Ren Fail. 2013;35(10):1353-7. doi: 10.3109/0886022X.2013.828262. Epub 2013 Aug 21.
9
The genetics of Henoch-Schönlein purpura: a systematic review and meta-analysis.过敏性紫癜的遗传学研究:系统评价和荟萃分析。
Rheumatol Int. 2013 Jun;33(6):1387-95. doi: 10.1007/s00296-012-2661-4. Epub 2013 Jan 17.
10
The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.霉酚酸酯联合皮质类固醇诱导过敏性紫癜肾炎缓解。
Am J Nephrol. 2012;36(3):271-7. doi: 10.1159/000341914. Epub 2012 Sep 7.